Sionna Therapeutics Stock Plunges After Cystic Fibrosis Trial Failure; Vertex Rises on Reduced Competition
Will not advance SION-719 add-on; Vertex sees relief from rivalry.
/ 9 items
#VRTX↓
Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
Casgevy Outlook: Morgan Stanley’s Take on CRISPR Therapeutics
Morgan Stanley upgraded CRISPR Therapeutics to Equal Weight, $60 target (~21% upside), sees Casgevy growth but mixed valuation views.
Why Investors Punished Maze Stock Despite Strong MZE829 Diabetes Data
Maze’s new kidney pill MZE829 cut harmful protein in urine by 35.6% in its Phase 2 trial — including patients with diabetes. Stock still fell 30% as analysts say “don’t compare it to Vertex” but remain very bullish.
Vertex's Povetacicept Delivers Solid IgAN Data — But No Real Threat to Vera's Atacicept, Says BofA
BofA reaffirms Buy on Vera Therapeutics; Vertex’s povetacicept Phase 3 interim results in IgAN meet expectations but pose no major competitive threat.
Vertex’s Povetacicept Hits Primary + All Secondary Endpoints in Phase 3 IgAN Trial
Vertex Pharmaceuticals' povetacicept succeeds in Phase 3 RAINIER trial for IgA nephropathy with 52% proteinuria reduction. Positive safety data and FDA submission planned soon.